By lowering the amount of cellular cholesterol, SREBP2 suppression by medication or genetics reduces the amount of ZIKV infection in monocyte-derived DCs (moDCs), possibly due to the reduction of ZIKV infection during the replication, assembly, and/or budding phases. Here, SREBF2 is linked to Zika virus infectious disease.